Prestige Consumer Healthcare (NYSE:PBH) Rating Reiterated by Jefferies Financial Group

Prestige Consumer Healthcare (NYSE:PBH)‘s stock had its “hold” rating reaffirmed by equities research analysts at Jefferies Financial Group in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $76.00 price objective on the stock, up from their previous price objective of $70.00. Jefferies Financial Group’s price objective would suggest a potential upside of 5.10% from the company’s previous close.

Separately, DA Davidson boosted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, August 28th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $94.20.

Prestige Consumer Healthcare Stock Down 1.0 %

Shares of Prestige Consumer Healthcare stock opened at $72.32 on Tuesday. The company has a 50-day simple moving average of $71.25 and a two-hundred day simple moving average of $69.65. The stock has a market capitalization of $3.59 billion, a PE ratio of 17.34, a price-to-earnings-growth ratio of 2.08 and a beta of 0.48. Prestige Consumer Healthcare has a 52-week low of $56.34 and a 52-week high of $75.80. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.90 and a current ratio of 3.23.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.90 earnings per share for the quarter, topping the consensus estimate of $0.86 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The firm had revenue of $267.10 million during the quarter, compared to analysts’ expectations of $260.54 million. During the same quarter in the previous year, the business earned $1.06 earnings per share. The company’s revenue was down 4.4% on a year-over-year basis. On average, analysts anticipate that Prestige Consumer Healthcare will post 4.42 EPS for the current fiscal year.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Hedge funds and other institutional investors have recently made changes to their positions in the business. Congress Asset Management Co. MA boosted its stake in shares of Prestige Consumer Healthcare by 596.2% during the 4th quarter. Congress Asset Management Co. MA now owns 679,256 shares of the company’s stock worth $41,584,000 after acquiring an additional 581,685 shares during the last quarter. Norges Bank bought a new stake in Prestige Consumer Healthcare during the fourth quarter valued at about $27,739,000. Ariel Investments LLC increased its position in Prestige Consumer Healthcare by 10.7% in the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after buying an additional 274,212 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in shares of Prestige Consumer Healthcare by 26.0% in the second quarter. Allspring Global Investments Holdings LLC now owns 1,320,125 shares of the company’s stock worth $90,891,000 after buying an additional 272,773 shares during the period. Finally, Victory Capital Management Inc. raised its stake in shares of Prestige Consumer Healthcare by 9.0% in the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock worth $142,827,000 after buying an additional 171,357 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.